|
|
|
Insider
Information: |
Leonard John M. |
Relationship: |
|
City: |
North Chicago |
State: |
IL |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
4 |
|
Direct
Shares |
1,085,175 |
|
Indirect Shares
|
64,888 |
|
|
Direct
Value |
$43,335,966 |
|
|
Indirect Value
|
$2,448,516 |
|
|
Total
Shares |
1,150,063 |
|
|
Total
Value |
$45,784,482 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
3
|
Stock
price went up :
|
0
|
1
|
Stock
price went down : |
0
|
2
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
81.1%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
![](../../../Gifs/iconPlus.jpg) |
Abbvie Inc. |
ABBV |
SVP, Chief Scientific ... |
2013-03-15 |
107,320 |
2013-03-15 |
6,473 |
Premium* |
![](../../../Gifs/iconPlus.jpg) |
Chimerix Inc |
CMRX |
Director |
2015-08-21 |
4,000 |
2016-09-15 |
0 |
Premium* |
![](../../../Gifs/iconPlus.jpg) |
IQVIA Holdings Inc |
IQV |
Director |
2024-05-07 |
13,783 |
2015-03-04 |
0 |
Premium* |
![](../../../Gifs/iconPlus.jpg) |
Intellia Therapeutics, Inc. |
NTLA |
|
2024-03-01 |
960,072 |
2024-03-01 |
58,415 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
75 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 3
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
NTLA |
Intellia Therapeutics, In... |
President and CEO |
|
2021-01-05 |
4 |
S |
$55.86 |
$348,511 |
D/D |
(6,239) |
475,488 |
0 |
% |
|
NTLA |
Intellia Therapeutics, In... |
President and CEO |
|
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,848 |
727,153 |
0 |
- |
|
NTLA |
Intellia Therapeutics, In... |
President and CEO |
|
2023-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,848 |
773,498 |
0 |
- |
|
NTLA |
Intellia Therapeutics, In... |
President and CEO |
|
2024-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,848 |
865,709 |
0 |
- |
|
ABBV |
Abbvie Inc. |
SVP, Chief Scientific Officer |
|
2013-02-19 |
4 |
D |
$37.58 |
$299,964 |
D/D |
(7,982) |
144,676 |
0 |
- |
|
NTLA |
Intellia Therapeutics, In... |
EVP, R&D |
|
2017-06-01 |
4 |
A |
$12.06 |
$101,322 |
I/I |
8,400 |
8,400 |
0 |
- |
|
NTLA |
Intellia Therapeutics, In... |
President and CEO |
|
2018-05-14 |
4 |
AS |
$24.00 |
$201,600 |
I/I |
(8,400) |
0 |
0 |
- |
|
ABBV |
Abbvie Inc. |
SVP, Chief Scientific Officer |
|
2013-02-28 |
4 |
D |
$36.73 |
$345,519 |
D/D |
(9,407) |
135,269 |
0 |
- |
|
NTLA |
Intellia Therapeutics, In... |
President and CEO |
|
2020-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,375 |
481,727 |
0 |
- |
|
NTLA |
Intellia Therapeutics, In... |
President and CEO |
|
2024-01-03 |
4 |
S |
$29.46 |
$566,310 |
D/D |
(19,223) |
846,486 |
0 |
% |
|
NTLA |
Intellia Therapeutics, In... |
President and CEO |
|
2020-11-16 |
4 |
OE |
$14.58 |
$291,600 |
D/D |
20,000 |
487,352 |
0 |
- |
|
NTLA |
Intellia Therapeutics, In... |
President and CEO |
|
2020-11-16 |
4 |
AS |
$34.00 |
$680,000 |
D/D |
(20,000) |
467,352 |
0 |
% |
|
IQV |
IQVIA Holdings Inc |
Director |
|
2019-12-20 |
4 |
AS |
$151.00 |
$3,090,600 |
D/D |
(20,200) |
8,252 |
0 |
- |
|
IQV |
IQVIA Holdings Inc |
Director |
|
2019-12-20 |
4 |
OE |
$64.52 |
$1,308,254 |
D/D |
20,200 |
28,452 |
0 |
- |
|
NTLA |
Intellia Therapeutics, In... |
President and CEO |
|
2021-08-19 |
4 |
OE |
$13.40 |
$303,939 |
D/D |
22,682 |
741,987 |
0 |
- |
|
NTLA |
Intellia Therapeutics, In... |
President and CEO |
|
2021-08-19 |
4 |
AS |
$150.46 |
$3,431,398 |
D/D |
(22,682) |
719,305 |
0 |
% |
|
NTLA |
Intellia Therapeutics, In... |
President and CEO |
|
2021-02-05 |
4 |
AS |
$67.18 |
$1,552,185 |
D/D |
(22,942) |
631,861 |
0 |
% |
|
ABBV |
Abbvie Inc. |
SVP, Chief Scientific Officer |
|
2013-02-19 |
4 |
D |
$37.58 |
$952,465 |
D/D |
(25,345) |
148,981 |
0 |
- |
|
NTLA |
Intellia Therapeutics, In... |
President and CEO |
|
2021-04-13 |
4 |
OE |
$6.83 |
$289,506 |
D/D |
25,937 |
719,305 |
0 |
- |
|
NTLA |
Intellia Therapeutics, In... |
President and CEO |
|
2021-08-23 |
4 |
AS |
$151.54 |
$4,125,416 |
D/D |
(27,139) |
719,305 |
0 |
% |
|
NTLA |
Intellia Therapeutics, In... |
President and CEO |
|
2021-08-23 |
4 |
OE |
$13.40 |
$363,663 |
D/D |
27,139 |
746,444 |
0 |
- |
|
ABBV |
Abbvie Inc. |
SVP, Chief Scientific Officer |
|
2013-03-08 |
4 |
S |
$37.50 |
$1,048,432 |
D/D |
(27,949) |
107,320 |
0 |
- |
|
NTLA |
Intellia Therapeutics, In... |
President and CEO |
|
2021-02-09 |
4 |
AS |
$75.00 |
$2,103,225 |
D/D |
(28,043) |
660,536 |
0 |
% |
|
ABBV |
Abbvie Inc. |
SVP, Chief Scientific Officer |
|
2013-02-19 |
4 |
OE |
$27.29 |
$809,267 |
D/D |
29,650 |
174,326 |
0 |
- |
|
ABBV |
Abbvie Inc. |
SVP, Chief Scientific Officer |
|
2013-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
30,360 |
152,658 |
0 |
- |
|
75 Records found
|
|
Page 2 of 3 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|